As a study director, Sandra works routinely on pre-clinical models such as PAH and COPD. Over the past three years she and her team have developed the implantation method of pressure telemetry probes in rats.
Connect with Sandra Gagnon
Non-alcoholic fatty liver disease (NAFLD)
Purpose
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. Metabolic syndrome is part of obesity, insulin resistance, dyslipidemia and physical inactivity. Its worldwide prevalence continues to increase with the growing epidemic of obesity and insulin resistance, and it is becoming the most common cause of chronic liver disease.
Method
NAFLD is induced by high fat diet or a combination of High fat, high fructose and cholesterol during a period of 8-12 weeks
Study outcome
Blood biochemistry profile, Glucose tolerance (OGTT), extensive liver histology profile, Liver triglyceride content
Species
Mice
Sandra Gagnon
Study Director
